Overview of Biopharmaceutical Segments
According to the National Strategic Emerging Industries Classification Directory, the biopharmaceutical industry can be divided into three subcategories: chemical drugs, modern traditional Chinese medicines (TCM) and biological drugs, of which modern TCM is divided into traditional Chinese medicines (TCM) and proprietary medicines (proprietary medicines), and biological drugs are further divided into vaccines, blood products, diagnostic reagents, monoclonal Antibodies, etc.
Supply of biopharmaceutical subcategories
--Chemical preparations output has rebounded
Experiencing a sudden drop in output due to the outbreak of the epidemic in 2020, China's 2021 production of chemical preparations rebounded. Among its five main types of dosage forms, production of powdered injections increased 2.5% to 8.15 billion vials in 2021; injections decreased 12.2% to 11.9 billion vials; infusions increased 4.5% to 14.18 billion vials; tablets increased 1.5% to 258.53 billion tablets; and capsules increased 14.2% to 85.52 billion capsules.
-- Production of proprietary Chinese medicines declined year by year
National production of proprietary Chinese medicines continued to decline from 2016 to 2022.In 2022, China's cumulative production of proprietary Chinese medicines reached 2.277 million tons, a decrease of 41,000 tons compared with 2021.
--Vaccine signing and wholesaling volume declined slightly, and plasma collection of blood products rebounded
With the rapid development of China's vaccine market, especially after several major epidemics, awareness of vaccines from the government to the public has been improved to different degrees. From the point of view of the total number of batches issued, from 2013 to 2019, China's vaccine batches issued showed a fluctuating trend. Affected by the new crown epidemic, the total vaccine wholesale issue in 2020 was 650 million units, an increase of 15.89% year-on-year, the growth rate is the highest in the past ten years. After the impact of the epidemic gradually weakened, China's wholesale volume by the limitations of R & D technology, will show a smooth fluctuation trend, 2022, a slight decline to 670 million units.
In 2006, the "work program on the conversion of single plasma stations" made it clear that the single plasma station was set up by the health administrative department instead of the blood products enterprises, and the plasma station established a "one-to-one" plasma supply relationship with the producer to accelerate the concentration of the industry. On July 18, 2007, the State Food and Drug Administration also issued the Notice on the Implementation of Quarantine Period for Raw Material Plasma for Blood Products Production, which required that since July 1, 2008, all plasma raw materials should be left to stand for more than 3 months (i.e., the industry called "window period"), and then be qualified by the virus test before being put into the material for production. Affected by the policy, the national plasma collection in 2007 fell nearly 50%. 2007-2022, by the standardized plasma station began to put into use, people's awareness of blood donation, China's plasma collection fluctuations in the upgrading trend, in 2022, the blood products industry plasma collection of more than 10,000 tons.
Demand for biopharmaceutical sub-products: chemical drugs dominate
China's chemical drug industry market size of about 883.9 billion yuan, accounting for 47% of the market size of the biopharmaceutical industry; China's traditional Chinese medicine industry market size of about 467.9 billion yuan, accounting for 25% of the market size of the Chinese medicine industry, accounting for 25% of the market size of China's biopharmaceutical industry market size of about 516.2 billion yuan, accounting for about 28%. In summary, the current market of China's biopharmaceutical industry, chemical drugs occupy a dominant position, but with the rapid development of the biopharmaceutical industry, the proportion of biological drugs will gradually increase, this pattern will be broken.
Biomedical segments product trends: the globalization of Chinese medicine products, biological drugs become a key growth point
Overall, a large part of China's biomedical technology is still stuck in the scientific research and has not been effectively converted into productive capacity, which not only wastes a lot of resources, but also makes China's production practice can not keep up with the R & D, resulting in a lagging production situation. From the point of view of product segments, chemical drugs are still dominant, Chinese medicine products have a globalization trend, and biological drugs have become the industry's key future growth point.
For more research and analysis of this industry, please refer to the "China Biomedical Industry Development Prospect Forecast and Investment Strategy Planning Analysis Report" by Prospect Industry Research Institute.